Past Issues
See what you've been missing. Browse every issue of our free, daily briefing.
52% tumor response: the "undruggable" cancer target just got drugged
For 40 years, KRAS was the protein oncologists couldn't touch. Revolution Medicines just posted data that nearly triples chemotherapy's benchmark, and the FDA already has it in the express lane. Plus: a two-drug HIV pill that came back from the dead, and $281 million in fresh bets on brains, blindness, and modified DNA.
Lilly just dropped $7B to build cancer treatment inside your body
Eli Lilly wrote another enormous check for a technology that could turn CAR-T therapy from a weeks-long manufacturing nightmare into a single IV drip. Meanwhile, the TIGIT graveyard claimed another victim, and a cancer-fighting virus company is fighting for survival after its second FDA rejection.
The drug target everyone abandoned just won its third Phase 3 trial
AstraZeneca just proved the entire industry wrong on a target that Roche and Sanofi couldn't crack. Meanwhile, Novo Nordisk quietly became a sickle cell disease company, and a rejected biotech is knocking on Wall Street's door again.
Lilly's obesity pill grabbed 1,400 scripts before pharmacies even stocked it
A weight-loss pill just posted opening-weekend numbers that would make a Marvel movie jealous, and it wasn't even available at most pharmacies yet. Meanwhile, the FDA managed to reject the same cancer drug twice and quietly unbanned a dozen peptides it called dangerous two years ago.
UCB bets $1.15B that transplanted brain cells can cure epilepsy
A Belgian pharma giant just paid over a billion dollars for a therapy that transplants lab-grown neurons into patients' brains, and the early data is wild. Meanwhile, OpenAI launched its first biology-specific AI model, Merck revealed its post-Keytruda survival plan, and a cancer drug that wears a molecular disguise just entered the clinic.
A pancreatic cancer drug just nearly doubled survival. Oncologists are stunned.
Revolution Medicines dropped Phase 3 data that almost no one thought was possible: a pill that nearly doubled survival in pancreatic cancer, the deadliest major malignancy in oncology. Meanwhile, a two-year-old company you've never heard of just pulled off the biggest biotech IPO in history, and a new report is calling Alzheimer's blockbuster drugs a bust.
A daily pill just doubled pancreatic cancer survival. Oncology is stunned.
A cancer that kills 97% of patients with metastatic disease just met a pill that nearly doubled survival times, cracking a target scientists called "undruggable" for four decades. Meanwhile, Big Pharma is handing AI companies the keys to the drug lab, and the FDA is cleaning house on compounded peptides.
A senator bet his life on an "undruggable" cancer drug. The data just landed.
A former U.S. senator enrolled in a trial for a drug that scientists said couldn't exist, and Phase 3 results show pancreatic cancer patients living nearly twice as long as those on chemo. Meanwhile, the FDA just sent 2,200 companies a not-so-friendly reminder about their missing trial data.
Lilly just paid $300M for a company with zero drugs in humans
Eli Lilly dropped up to $300 million on a two-year-old startup that hasn't tested a single drug in people. Meanwhile, AbbVie is shopping for painkillers in China, two obesity and proteomics companies want nearly $700M combined from public markets, and Big Pharma quietly took out the immunology trash.
The protein that stumped cancer researchers for 40 years just lost a fight
A cancer target that scientists literally gave up on just got beaten in a Phase 3 trial, with results so strong they might reshape oncology's most stubborn tumor types. Plus: the FDA fast-tracks a guided-missile drug for the deadliest lung cancer, Regeneron crashes the radioactive drug party, and two biotechs ring the IPO bell on the same day.
Western pharma went on a China biotech shopping spree to start 2026
Big Pharma is buying Chinese biotech innovation at a pace that would make Black Friday shoppers blush, pouring billions into licensing deals before most people finished their New Year's resolutions. Meanwhile, Gilead announced $13 billion in deals in six weeks, the FDA blessed a needle-free weight loss pill, and biotech's IPO window is officially back open.
The FDA rejected this melanoma drug twice, even with breakthrough status
A cancer drug with genuinely impressive data just got its second FDA rejection, and the reason has nothing to do with whether it works. Meanwhile, a single canceled FDA meeting killed an entire biotech company. Grab your coffee; today's newsletter is a masterclass in regulatory risk.
A cancer therapy just wiped out three autoimmune diseases in one patient
A woman who needed daily blood transfusions had three autoimmune diseases erased by a single CAR-T infusion. Her immune system essentially rebooted itself. Meanwhile, gut bacteria might be giving people ALS, biotech VCs are having an existential crisis, and the nation's top health official has a peptide problem.
Roche just bought 2,176 GPUs. That's more than some countries own.
Roche built the biggest supercomputer in pharma history, and it's not even close. Meanwhile, two pharma giants placed billion-dollar bets on protein degradation within 24 hours of each other, and the GLP-1 price war just entered a new phase that could change how 40% of American adults access obesity drugs.
The FDA's favorite AI tool just got banned from U.S. healthcare
The most safety-conscious AI company in tech got kicked out of every federal health agency, not for a security flaw, but for telling the Pentagon "no." Meanwhile, Europe wrote its biggest biotech check ever, and a condition with zero approved drugs just found its first real lead.
Gilead turns a $20M option deal into a major ADC bet
Gilead's exclusive option and license agreement with a Munich startup most people have never heard of caps a wild week of billion-dollar dealmaking, FDA dysfunction that literally killed a company, and AI making moves that blur the line between tech firm and drug developer. Buckle up.
Big pharma dropped $20B in March alone, and April's not slowing down
Three mega-acquisitions worth over $20 billion landed in a single month, making March 2026 one of the most frenzied stretches of biotech dealmaking in recent memory. Meanwhile, the White House is using 100% drug tariffs as a bargaining chip, a stealth oncology startup just debuted with $100 million, and scientists found a single protein that actually reverses brain aging in mice.
The FDA just approved a drug that sneaks past the brain's bouncer
A rare disease therapy just pulled off something no enzyme replacement has done before: crossing the blood-brain barrier. Meanwhile, the FDA commissioner wants to rewrite the rulebook on drug approvals, MIT open-sourced an AI that screens drugs 1,000x faster, and GSK poached Sanofi's top vaccine scientist.
The drug pipeline just shrank for the first time in 30 years
For three decades, the global biopharma pipeline did exactly one thing: grow. That streak just ended, and the forces behind the reversal tell a much bigger story about where the industry is headed. Plus: a $15 billion budget threat, Big Pharma's tariff escape hatch, and a CAR-T milestone.
Lilly's $25/month obesity pill just killed the needle era
The FDA just approved an obesity pill that costs less than your Netflix subscription, and it doesn't require a single needle. Meanwhile, the White House is threatening to double the price of imported drugs overnight, and a gene editor that works like a pencil just aced the biggest test in medicine.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.